RNS Number : 7147D Renalytix PLC 01 July 2021 Renalytix plc (" Renalytix " or the " Company ") Total voting rights The Company's total issued share capital consists of 72,197,286 shares of 0.25 pence each, with each share carrying the right to one vote.
Study Results lay foundation for KidneyIntelX repeat testing, reimbursement, and pharma collaborations NEW YORK, June 28, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX) (NASDAQ: RNLX) announces new data demonstrating KidneyIntelX™ can be effective at monitoring therapeutic response and
RNS Number : 3397D Renalytix PLC 28 June 2021 Renalytix plc ("Renalytix" or the "Company") Director/PDMR Dealing The Company had been informed today that Christopher Mills , a non-executive director and interim Chairman, completed the sale of 6,100 ordinary shares of 0.25 pence each
RNS Number : 2844D Renalytix PLC 28 June 2021 Renalytix plc (" Renalytix " or the " Company ") KidneyIntelX TM Enables Monitoring of SGLT2 Inhibitor Therapy Response and Corresponding Risk Reduction Over Time Study Results lay foundation for KidneyIntelX repeat testing, reimbursement, and
RNS Number : 2249D Renalytix PLC 25 June 2021 Renalytix plc ("Renalytix" or the "Company") Director/PDMR Dealing The Company was informed that today, Fergus Fleming , Chief Technology Officer, completed the sale of 15,000 ordinary shares of 0.25 pence each ("Ordinary Shares") in the
RNS Number : 1945D Renalytix PLC 25 June 2021 Renalytix plc (" Renalytix " or the " Company ") Exercise of options and total voting rights NEW YORK , June 25, 2021 - Renalytix plc (LSE: RENX) (NASDAQ: RNLX) announces that it has issued and allotted 150,000 ordinary shares of 0.25 pence
RNS Number : 0409D Renalytix AI PLC 24 June 2021 Renalytix AI plc (" Renalytix " or the " Company ") Change of name to Renalytix Plc Change of registered office Change of website NEW YORK , June 24, 2021 - Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) announces it has changed its name to
RNS Number : 7366C Renalytix AI PLC 22 June 2021 The following amendment(s) has been made to the ' Director/PDMR Dealing ' announcement released on 22 June 2021 at 10:57 under RNS No 7062C. The price of 113.5 pence per share was incorrect and has been amended to 1135 pence per share.
RNS Number : 7062C Renalytix AI PLC 22 June 2021 Renalytix AI plc ("Renalytix" or the "Company") Director/PDMR Dealing The Company was informed that today, Christopher Mills , a non-executive director and interim Chairman, completed the sale of 17,000 ordinary shares of 0.25 pence each
NEW YORK, June 15, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) (“Renalytix” or the “Company”) today reported financial results for the quarter and nine months ended March 31, 2021. Recent Highlights Partnership announced with University of Utah health system to improve